clinical trial · NCT05579184
[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2
FutureChem·phase2·active not recruiting·n = 20
Metastatic Castration-resistant Prostate Cancer, mCRPC[177Lu]Ludotadipep
brief summary
100 mCi of \[177Lu\]Ludotadipep, the dose determined in the phase 1 clinical trial (FC705-1), was administered repeatedly up to 6 times at intervals of 8 weeks (±2 weeks) to patients with metastatic castration resistant prostate cancer (mCRPC) in order to assess the safety and efficacy.
started
Oct 30, 2022
primary completion
Dec 31, 2024
completion
Dec 31, 2024
last updated
Apr 29, 2024
official title
Phase 2 Study of Repeat-dose [177Lu]Ludotadipep Treatment for Metastatic Castration-resistant Prostate Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol